

# Rebecca Dent

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/680130/publications.pdf>

Version: 2024-02-01

33  
papers

6,164  
citations

394286

19  
h-index

395590

33  
g-index

34  
all docs

34  
docs citations

34  
times ranked

9025  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110666.	1.4	16
2	Association between Breast Cancer Polygenic Risk Score and Chemotherapy-Induced Febrile Neutropenia: Null Results. <i>Cancers</i> , 2022, 14, 2714.	1.7	2
3	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	5.1	260
4	Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers. <i>PLoS ONE</i> , 2021, 16, e0250102.	1.1	11
5	Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 377-386.	1.1	38
6	Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. <i>Science Advances</i> , 2021, 7, eabh2443.	4.7	42
7	Understanding the Psychological Impact of COVID-19 Pandemic on Patients With Cancer, Their Caregivers, and Health Care Workers in Singapore. <i>JCO Global Oncology</i> , 2020, 6, 1494-1509.	0.8	95
8	Early-onset breast cancer in a woman with a germline mobile element insertion resulting in BRCA2 disruption: a case report. <i>Human Genome Variation</i> , 2020, 7, 24.	0.4	3
9	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1012-1024.	1.5	11
10	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.4	3
11	Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 604688.	1.1	12
12	Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. <i>Journal of Clinical Pathology</i> , 2020, 73, 557-562.	1.0	53
13	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. <i>PLoS ONE</i> , 2019, 14, e0221305.	1.1	14
14	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	1.1	58
15	Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. <i>Psycho-Oncology</i> , 2018, 27, 1185-1192.	1.0	42
16	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 713-721.	1.1	20
17	Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1008-1008.	0.8	24
18	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1360-1372.	5.1	377

#	ARTICLE	IF	CITATIONS
19	Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. <i>Lancet Oncology</i> , The, 2017, 18, e638.	5.1	7
20	Novel Targeted Agents and Immunotherapy in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 65-75.	1.8	8
21	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 34-42.	1.8	85
22	Association of <i>CYP2C19</i> and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1142-1152.	1.1	18
23	Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1239-1250.	1.6	27
24	Ten-year survival in women with primary stage IV breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 145-152.	1.1	88
25	Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. <i>Neuro-Oncology</i> , 2016, 18, 244-251.	0.6	71
26	Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study. <i>International Journal of Cancer</i> , 2015, 137, 2504-2512.	2.3	28
27	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 232-241.	0.5	0
28	Role of inflammatory infiltrates in triple negative breast cancer: Table 1. <i>Journal of Clinical Pathology</i> , 2015, 68, 506-510.	1.0	89
29	Platinum-based chemotherapy in triple-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 567-572.	1.1	28
30	Weighed, Measured, and Still Searching: Bevacizumab in the Treatment of Unselected Patients with Advanced Breast Cancer. <i>Oncologist</i> , 2011, 16, 1669-1671.	1.9	3
31	Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design. <i>Clinical Breast Cancer</i> , 2009, 9, 29-33.	1.1	367
32	Pattern of metastatic spread in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 423-428.	1.1	455
33	Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. <i>Clinical Cancer Research</i> , 2007, 13, 4429-4434.	3.2	3,807